Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ADA Meeting's Around The Corner: Five Things To Watch For

Executive Summary

Among other debates at the American Diabetes Association annual meeting, clinicians will discuss the future of cardiovascular outcomes studies for diabetes drugs – whether they should maintain course or are due for an overhaul.

You may also be interested in...



Novo Nordisk's Oral Semaglutide Succeeds In First Phase III, But Prompts Questions

In PIONEER 1, weight loss results for the oral version of the GLP-1 agonist were somewhat disappointing and lack of detail in the top-line release prompts concerns about compliance.

Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic

Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).

Biocon’s Oral Insulin Gains Momentum With JDRF Backing

Biocon’s oral insulin program has received a boost with the US-based JDRF supporting plans to progress its drug candidate in type 1 diabetes. While the pullback of players like Novo Nordisk underscores the potential risks in the oral insulin space, JDRF says early results of Biocon’s candidate “warrant support” for further studies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131499

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel